Pipeline

September 16, 2019
Company Drug/Device Medical Condition Status
Selvita SEL120 acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) Phase 1b trial initiated enrolling subjects at sites across the U.S.
VBI Vaccines Inc. VBI-1901 in combination with GlaxoSmithKline’s proprietary AS01B adjuvant system recurrent glioblastoma (GBM) Phase 2a trial initiated enrolling 20 subjects with first-recurrent GBM only
Recardio, Inc. dutogliptin in combination with filgrastim post-myocardial infarction Phase 2 trial initiated enrolling 140 subjects at specialized cardiology centers located throughout Europe and the U.S.
Alector, Inc. AL001 frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN) Phase 2 trial initiated enrolling 32 subjects with FTD-GRN and an additional cohort of FTD subjects with a C9orf72 mutation (FTD-C9orf72)
Biohaven Pharma Holding Company Ltd. vazegepant acute treatment of migraine Phase 2/3 trial initiated
Lipidor AB Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01) mild to moderate psoriasis Phase 3 study initiated enrolling 277 subjects at 14 clinics across India
Functional Neuromodulation fornix (DBS-f) mild Alzheimer's Disease Phase 3 study initiated enrolling 210 people 65 years or older with mild Alzheimer's disease at 14 study sites in the U.S., Canada and Germany
EMD Serono evobrutinib relapsing multiple sclerosis (RMS) Two phase 3 studies initiated enrolling 1,900 adult subjects
Nevakar Inc. NVK-002 slow the progression of myopia in children Phase 3 study initiated enrolling 576 child subjects aged 3 to 17 years in Asia, the U.S. and Europe
Netech Delta 3300 arrhythmia 510(k) approval granted by the FDA
Merck KGaA tepotinib metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy Designation granted by the FDA
Horizon Therapeutics plc teprotumumab active thyroid eye disease (TED) Priority Review granted by the FDA
Almirall LLC Aczone 7.5% topical gel acne vulgaris Approval granted by the FDA
Jenkins Eye Care AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL) cataract Approval granted by the FDA
Axonics Modulation Technologies, Inc. implantable rechargeable sacral neuromodulation (“SNM”) device urinary and bowel dysfunction Approval granted by the FDA
Boehringer Ingelheim Pharmaceuticals Ofev (nintedanib) capsules interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD) Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here